Trastuzumab Introduction The ability of antibodies to provide targeted therapies with low immunogenicity has driven impressive growth in the number of monoclonal antibody (mAb) therapeutics in clinical trials and approved by the United States Food and Drug Administration (FDA) (Ecker do not perform thes...